Testing lenalidomide for mild cognitive impairment
Treatments studied
Part of Brain & nervous system, Genetic & congenital, Mental health clinical trials.
This trial tests an oral drug called lenalidomide (often used for immune conditions) to see if it can help people with early memory loss due to Alzheimer's. You would need a study partner, be willing to have spinal taps and brain scans, and have a positive amyloid PET scan.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 50 to 89 years old and have been told you have mild cognitive impairment (MCI) that affects your memory.
- You have a positive brain scan for amyloid protein (a sign of Alzheimer's disease).
- You must have a reliable family member or friend who can help you with visits and medicine.
- You are able to swallow pills and undergo lumbar puncture (spinal tap), MRI, and PET scans.
- You don't live alone, and you don't have serious heart, lung, liver, kidney, or blood disorders.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug, QLH2405, for people with mild cognitive impairment or mild Alzheimer's disease. It aims to see if the drug is safe and how it affects memory and thinking.
This trial tests an investigational drug called Neuroaid II (MLC901) for people with mild to moderate Alzheimer's disease. It aims to see if the drug can help slow down memory and thinking problems.
This trial tests a new drug called CM383 in people with mild cognitive impairment or mild Alzheimer's disease. The goal is to see if it can help slow down memory loss.
This study tests a new medicine, NVP-NK4146, for people with mild cognitive impairment (MCI) due to Alzheimer's disease. The goal is to see if it can help slow down memory and thinking problems.
This study tests an experimental oral medication (EI-1071) to see if it can reduce brain inflammation in people with Alzheimer's disease. The goal is to learn if it is safe and might help slow cognitive decline.
This study tests whether a new drug called Latrepirdine (DMB-I) is safe and effective for people with mild to moderate Alzheimer's dementia. It may help slow cognitive decline when added to current treatment or used alone.
Hear when a new Cognitive Dysfunction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.